|Bid||0.0000 x 1800|
|Ask||0.0000 x 1300|
|Day's Range||0.1500 - 0.1500|
|52 Week Range||0.1300 - 4.0000|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.25|
Subscribe to Yahoo Finance Plus to view Fair Value for EMMA
Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced a collaboration with the Steve Harvey Morning Show cast member Kier (Junior) Spates to share Mr. Spates' personal experience with the use of Endari®, Emmaus' prescription L-glutamine oral powder, to treat his sickle cell disease, or SCD.
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT Emmaus Life Sciences, Inc. (OTC:EMMA) is expanding the reach of Endari, its treatment for sickle cell disease, while also pursuing other treatments to add to its portfolio. The company had shown the ability of bringing a treatment to commercialization and we believe the market is not fully recognizing the potential Emmaus has to